Milk Thistle for Liver Health

Verdict: Weak evidence; unproven for general liver health

Milk thistle (silymarin) modestly lowers liver enzymes in specific conditions like fatty liver disease, but there is no good evidence it protects, "detoxes," or improves general liver health, and major clinics say it hasn't been proven to work.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The evidence is genuinely condition-specific rather than broadly supportive. Moderate-quality meta-analyses show silymarin significantly lowers the liver enzymes ALT and AST in fatty liver disease (PMID 38579127, 26 RCTs, n=2375; PMID 38505782) and cuts the risk of anti-tuberculosis drug-induced liver injury (PMID 30733935, RR 0.33). But a 29-trial systematic review found only 65.5% of studies reported any enzyme reduction, with optimal dose and target population still undefined (PMID 38021897).

Crucially, these benefits rest on a surrogate marker: lower ALT/AST does not prove silymarin reverses fibrosis, prevents liver failure, or extends survival. For the vague consumer claim of general liver protection or detox, the evidence is weak, and a toxicology review found support only for intravenous silibinin in Amanita mushroom poisoning, with no feasible RCTs (PMID 36222816).

Authorities reinforce the cautious grade. Mayo Clinic states milk thistle is generally safe but "hasn't proved effective for improving liver health," while liver-disease specialty societies do not recommend it and frame supplements mainly as a cause of liver injury. The FDA has rejected therapeutic liver claims and EFSA placed its liver-function claim on hold, so a Weak (C) grade fits: real but small, surrogate-only, inconsistent evidence for narrow uses, and an unproven general-support claim.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.43
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
80%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.34
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.431
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis
PMID: 38579127 2024 統合分析 n = 2,375
Finding: Across 26 RCTs silymarin significantly reduced ALT (by ~12.39 U) and AST (by ~10.97 U), improved hepatic steatosis (OR 3.25), and lowered total cholesterol (SMD -0.85), triglycerides (SMD -0.62) and LDL-C (SMD -0.81) in NAFLD/NASH patients.
Effect size: ALT -12.39 U; AST -10.97 U; hepatic steatosis OR 3.25
View on PubMed
Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
PMID: 38505782 2024 統合分析
Finding: Silymarin significantly reduced ALT (MD -17.12, 95% CI -28.81 to -4.43, p<0.004) and AST (MD -12.56, 95% CI -19.02 to -6.10, p<0.0001) and triglycerides; GGT showed no significant difference (p=0.07); LDL, total cholesterol, HOMA-IR and BMI unchanged.
Effect size: ALT MD -17.12; AST MD -12.56; GGT NS
View on PubMed
Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials
PMID: 30733935 2019 統合分析 n = 1,198
Finding: Across 5 RCTs (585 silymarin, 613 placebo) silymarin significantly reduced anti-TB DILI risk at week 4 (RR 0.33, 95% CI 0.15 to 0.75) with small protective effects on ALT (SMD -0.15), AST (SMD -0.14) and ALP (SMD -0.12); adverse event rates similar between groups.
Effect size: DILI RR 0.33 (95% CI 0.15-0.75) at week 4
View on PubMed
Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review
PMID: 38021897 2023 系統性回顧 n = 3,846
Finding: Of 29 RCTs (3,846 participants, conditions 1992-2023), 65.5% reported reduced liver enzymes, 20.7% no significant change, and 13.8% elevated enzymes; authors concluded silymarin shows potential hepatoprotection but optimal dose and target populations remain undefined.
🟠 Limited quality Effect size: 65.5% of studies showed reduced enzymes; mixed overall
View on PubMed
Silibinin: a toxicologist's herbal medicine?
PMID: 36222816 2022 系統性回顧
Finding: Evidence is strongest for IV silibinin as supportive therapy in Amanita phalloides (amatoxin) poisoning, where it blocks hepatic uptake of alpha-amanitin; however no RCTs exist for this indication and data rely on animal studies, case series and retrospective reviews. For general hepatoprotection the evidence base remains weak.
🟠 Limited quality Effect size: not quantified (no RCTs feasible for Amanita poisoning)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Notice does not provide a basis for a GRAS determination source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
水飛薊素(silymarin)是水飛薊種子所提煉出的多種類黃酮總稱,被認為具有保肝的功效。在某些國家作為保肝的處方藥品,有些國家則作為保健食品。 source↗
L4e WHO
Neutral
Fructus Silybi Mariae consists of the dried ripe fruits, freed from the pappus, of Silybum marianum (L.) Gaertn. (Asteraceae). [WHO Monographs on Selected Medicinal Plants, Volume 2, 2002] source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Milk thistle is generally safe, but it hasn't proved effective for improving liver health. source↗
L5c Cleveland Clinic
Neutral
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-liver-health-INT-milk-thistle-001 繁體中文版 →